Drug Manufacturers—Specialty & Generic Industry | Healthcare Sector | - CEO | XSHE Exchange | CNE000001L31 ISIN |
China Country | 856 Employees | - Last Dividend | 4 Jul 2019 Last Split | - IPO Date |
Beijing SL Pharmaceutical Co., Ltd., established in 1994 under its former name Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd., and underwent a name change in 1998 to its current designation. Operating from the heart of Beijing, in the People’s Republic of China, this biopharmaceutical entity engages profoundly in the realms of research, development, production, and international marketing of genetic engineering drugs and its related products. Serving not only the domestic market of China but also catering to international demands, the company has established itself as a significant player in the biopharmaceutical sector.
Beijing SL Pharmaceutical Co., Ltd. offers a comprehensive range of formulations and active pharmaceutical ingredients (APIs), catering to various therapeutic areas:
Apart from finished formulations, Beijing SL Pharmaceutical Co., Ltd. also specializes in the production of high-quality active pharmaceutical ingredients (APIs), thereby contributing vitally to the pharmaceutical industry's supply chain both domestically and internationally.